The effect of trimetazidine on histological and myocardial disorders in rats
  • Article Type: Research Article
  • Eurasian Journal of Biosciences, 2020 - Volume 14 Issue 1, pp. 283-286
  • Published Online: 03 Mar 2020
  • Open Access Full Text (PDF)


Cardiac muscle anemia affects the functions of mitochondria that results in ion disparity. The condition called cardiac arrhythmia. The research aims to study the effect of antianginal medication of trimetazidine on myocardial disorders in rats. The study was conducted on the rats. They were fed with 10 mg trimetazidine per Kg weight of mice each day for seven days. Tests were done for the effect of the moderator on mitochondrial metabolism in severe cardiac muscle anemia affected rats. Acute cardiac muscle anemia results in an injury to mitochondrial functions. So, when anemia cluster without trimetazidine treatment was observed, a major reduction within the infarction range was ascertained in trimetazidine-treated anemia cluster (31±3% vs. 52.8±4.89%). Trimetazidine maintained the mitochondrial organization. And, thus, better the metabolic process management, magnitude relation, and sophisticated activity. Moreover, the mitochondrial biosynthesis and division or fusion of the cells improved. The indubitable Promote the activated receptor gamma peroxisome proliferator (PPARγ), the Joint Co-1α (PGC-1α), mitofusins one (Mfn1), dynamin-related super molecule one (Drp1), Optic nerve atrophy one (OPA1) emerge in rats with acute cardiac muscle anemia. Therefore, the incontestable heart defending effects of trimetazidine was shown to preserve mitochondrial metabolic process, increased biogenesis, and split/union of cells. And, thus, this rat model of cardiac muscle anemia may be effectively used along with other cardioprotective agents.


  • Ayyıldız A, Ayyıldız SN, Benli E, Erdem H, Cirrik S, Noyan T, et al. (2016) The effect of oral and intraurethral trimetazidine use on urethral healing. Iranian Journal of Basic Medical Sciences 19: 932-9.
  • Birch-Machin MA, Briggs HL, Saborido AA, Bindoff LA, Turnbull DM (1994) An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochemical Medicine and Metabolic Biology, 51: 35-42.
  • Compton SJ, Jones CG (1985) Mechanism of dye response and interference in the Bradford protein assay. Analytical Biochemistry 151: 369-74.
  • Harpey C, Clauser P, Labrid C, Freyria JL, Poririer J (1989) Trimetazidine, a cellular anti-ischemic agent. Cardiovascular Drug Reviews 4: 292-312.
  • Johnson CL, Mauritzen CM, Starbuck WC, Schwartz A (1967) Histones and mitochondrial ion transport. Biochemistry 6: 1121-7.
  • Kim SC, Boehm O, Meyer R, Hoeft A, Knüfermann P, Baumgarten G (2012) A murine closed-chest model of myocardial ischemia and reperfusion. Journal of Visualized Experiments 65: e3896.
  • Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W et al. (2016) The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism 65: 122-30.
  • Lopaschuk GD, Barr R, Thomas PD, Dyck JR (2003) Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circulation Research 93: e33-7.
  • Ma N, Bai J, Zhang W, Luo H, Zhang X, Liu D, et al. (2016) Trimetazidine protects against cardiac ischemia/reperfusion injury via effects on cardiac miRNA-21 expression, Akt and the Bcl-2/Bax pathway. Molecular Medicine Reports 14: 4216-22.
  • Mahfoudh Boussaid A, Selmi R, Bejaoui M, Hadj Ayed K, Zaouali MA, Ben Abdennebi H (2016) Effectiveness of a single versus repeated administration of trimetazidine in the protection against warm ischemia/reperfusion injury of rat liver. The Turkish Journal of Medical Sciences 46: 1258-64.
  • McCarthy CP, Mullins KV, Kerins DM (2016) The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. European Heart Journal – Cardiovascular Pharmacotherapy 2: 266-72.
  • McClellan KJ, Plosker GL (1999) Trimetazidine. A review of its use instable angina pectoris and other coronary conditions. Drugs 58: 143-57.
  • Mozaffari MS, Liu JY, Abebe W, Baban B (2013) Mechanisms of load dependency of myocardial ischemia reperfusion injury. American Journal of Cardiovascular Disease 3: 180-96.
  • Ruiz-Meana M, Garcia-Dorado D, Julia M, Gonzalez MA, Inserte J, Soler-Soler J (1996) Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovascular Research 32: 587-92.
  • Skemiene K, Liobikas J. Borutaite V (2015) Anthocyanins as substrates for mitochondrial complex I - protective effect against heart ischemic injury. FEBS J 282: 963-71.
  • Souidi N, Stolk M, Seifert M (2013) Ischemia-reperfusion injury: beneficial effects of mesenchymal stromal cells. Current Opinion in Organ Transplantation 18: 34-43.
  • Tetik C, Özden A, Calli N, Bilgihan A, Bostanci B, Yis O et al. (1999) Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats. Transplant International 12: 108-12.
  • Zhang N, Lei J, Liu Q, Huang W, Xiao H, Lei H (2015) The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology 131: 86-96.


This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.